"Anemia and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients"

We analyzed the effect of anemia on tumor response of patients with primary invasive breast cancer (BC) receiving neoadjuvant chemotherapy (NACT). The patient collective was very homogenous; finally, 74 BC patients with identical medication and duration of NACT were enrolled. After completion of NAC...

Full description

Saved in:
Bibliographic Details
Published inCancer investigation Vol. 39; no. 6-7; pp. 457 - 465
Main Authors Danzinger, Sabine, Fügerl, Alexandra, Pfeifer, Christian, Bernathova, Maria, Tendl-Schulz, Kristina, Seifert, Michael
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 09.08.2021
Subjects
age at diagnosis
Breast cancer
cancer-related anemia
neoadjuvant chemotherapy
tumor response
age at diagnosis
neoadjuvant chemotherapy
Breast cancer
cancer-related anemia
tumor response
Online AccessGet full text

Cover

More Information
Summary:We analyzed the effect of anemia on tumor response of patients with primary invasive breast cancer (BC) receiving neoadjuvant chemotherapy (NACT). The patient collective was very homogenous; finally, 74 BC patients with identical medication and duration of NACT were enrolled. After completion of NACT, 49 patients (66.2%) had a post-NACT Hb level <12 g/dl. In the anemic group, we found a tendency of lower median tumor response compared to nonanemic patients at this time (15 versus 17 mm, retrospectively, p = 0.18). Age at diagnosis significantly correlated with the difference of Hb [before initiation - after completion of NACT] (correlation coefficient = 0.40, p < 0.001).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0735-7907
1532-4192
DOI:10.1080/07357907.2021.1928166